This hypothesis is also supported by recent evidence showing that PFI-3, a selective SMARCA4/2 BRDi, fails to phenocopy the observed SMARCA2-depleted phenotype in SMARCA4-deficient lung cancer cells. This evidence concerns the gene SMARCA4 and lung carcinoma.